

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0050
Drug name and formulations:		Incruse® Ellipta® 55mcg
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	No issues
Clinical effectiveness	<i>Established licensed product</i>	Equivalent to established products.
Strength of evidence		Moderate
Cost effectiveness or resource impact	£	Cost neutral compared to Breezhaler® and Genuair® devices, cost saving compared to Handihaler® device.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	In line with other LAMA options, treatment pathway outlined in COPD guidelines.
National guidance and priorities	<i>NICE, MTRAC</i>	Consistent with the Global Initiative for Obstructive Lung Disease (GOLD) guidelines updated in 2017, and the NICE COPD Clinical Guideline.
Local health priorities	<i>CCG views</i>	CCGs supportive.
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	N/A

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	Green
Implementation requirements:	
Implementation monitoring:	